3/12
02:10 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/11
12:19 pm
blue
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
3/11
01:21 am
blue
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders
3/7
10:36 am
blue
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WBA, IVAC, BLUE on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WBA, IVAC, BLUE on Behalf of Shareholders
3/4
02:09 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/3
01:40 pm
blue
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
2/25
06:07 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
2/24
07:22 pm
blue
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
Low
Report
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
2/24
01:26 pm
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Wells Fargo & Company from $40.00 to $5.00. They now have an "equal weight" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Wells Fargo & Company from $40.00 to $5.00. They now have an "equal weight" rating on the stock.
2/24
07:07 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating.
2/21
03:43 pm
blue
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.
Low
Report
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.
2/21
01:55 pm
blue
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker [CNBC]
Low
Report
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker [CNBC]
2/21
12:30 pm
blue
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUE
Medium
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUE
2/21
12:02 pm
blue
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders
Medium
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders
2/21
09:02 am
blue
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders
Low
Report
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders
2/21
08:52 am
blue
BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders
Low
Report
BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders
2/21
07:30 am
blue
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
High
Report
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
2/18
04:03 am
blue
LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors [Yahoo! Finance]
Medium
Report
LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors [Yahoo! Finance]
2/14
09:15 am
blue
Adrenoleukodystrophy Drugs Market Projected to Reach USD 2.3 Billion by 2035, Boosted by Rising Investment in Biotechnology and Precision Medicine - Report by Transparency Market Research, Inc. [Yahoo! Finance]
Medium
Report
Adrenoleukodystrophy Drugs Market Projected to Reach USD 2.3 Billion by 2035, Boosted by Rising Investment in Biotechnology and Precision Medicine - Report by Transparency Market Research, Inc. [Yahoo! Finance]
1/30
09:34 am
blue
Latest Report by TMR Predicts Advanced Therapy Medicinal Products (ATMPs) Market to Surge with 16.6% CAGR, Expected to Reach US$ 245.1 Billion by 2034 | Uncover Future Trends in Healthcare [Yahoo! Finance]
Low
Report
Latest Report by TMR Predicts Advanced Therapy Medicinal Products (ATMPs) Market to Surge with 16.6% CAGR, Expected to Reach US$ 245.1 Billion by 2034 | Uncover Future Trends in Healthcare [Yahoo! Finance]
12/31
08:22 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its price target raised by analysts at Barclays PLC from $2.00 to $40.00. They now have an "overweight" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its price target raised by analysts at Barclays PLC from $2.00 to $40.00. They now have an "overweight" rating on the stock.
12/20
02:03 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/19
08:07 am
blue
March Biosciences Elects Peter Olagunju as Chair of Board of Directors [Yahoo! Finance]
Low
Report
March Biosciences Elects Peter Olagunju as Chair of Board of Directors [Yahoo! Finance]